Shanghai Rightongene Biotechnology (688217.SH) plans to provide housing for the actual controller and some key executives on a rent-to-own basis to help key talents have a place to live.
Ruiang Gene (688217.SH) announced that the company plans to cooperate with related parties Gaoshang Xian, Li Yunhang, Sun Yanbo, Zhang Cheng...
Shanghai Rightongene Biotechnology (688217.SH) announced that the company plans to sign "Public Rental Housing Lease-Purchase Contracts" with related parties Gaoshangxian, Li Yunhang, Sun Yanbo, and Zhang Chengli. The above-mentioned related parties intend to lease and purchase part of the properties located at No.19 of Lane 1288 Guangfeng Road, Fengxian District, Shanghai (Guangfeng Mingdu) from the company for residential use. The properties to be leased and purchased by Gaoshangxian, Li Yunhang, Sun Yanbo, and Zhang Chengli all have a building area of 101.98 square meters, with a lease term of 10 years. The total amount of the four contracts is approximately 9.5806 million yuan (including a total rental amount of 878,400 yuan for the leased properties over 10 years, and a total purchase amount of 8.7022 million yuan after the lease term expires).
It is reported that Gaoshangxian is one of the actual controlling persons of the company, a director, acting chairman, acting general manager, and acting legal representative of the company; Sun Yanbo is a director of the company; Li Yunhang is the chairman of the company's board of supervisors and a worker representative supervisor; Zhang Chengli is the vice general manager of the company.
The company stated that leasing or selling properties to related parties will help core talents of the company to achieve "housing security", attract and retain outstanding talents, enhance the company's talent competitiveness, and has reasonable business reasons.
Related Articles

Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ): Employee strategic placement asset management plan proposes to reduce holdings by no more than 550,600 shares.

INNOCARE (688428.SH): Apremilast treatment for systemic lupus erythematosus reaches Phase IIb study primary endpoint.

Baotou Huazi Industry (600191.SH) plans to sell Huazi Hotel and its affiliated marketing building for a price of 29.1 million yuan.
Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ): Employee strategic placement asset management plan proposes to reduce holdings by no more than 550,600 shares.

INNOCARE (688428.SH): Apremilast treatment for systemic lupus erythematosus reaches Phase IIb study primary endpoint.

Baotou Huazi Industry (600191.SH) plans to sell Huazi Hotel and its affiliated marketing building for a price of 29.1 million yuan.

RECOMMEND

Valued At $10 Trillion, The Largest IPO In History Is Coming As SpaceX Announces Listing Plan
12/12/2025

Five Imperatives And Eight Tasks: Central Meeting Specifies Next Year’s Economic Work, Highlights Identified
12/12/2025

Over 100 New Listings In Hong Kong This Year As Total Fundraising Tops HKD 270 Billion, Eighteen “A+H” Dual Listings
12/12/2025


